CompletedNCT01018056
D-serine or riluzole for Tourette syndrome
About this title
Read the official source — NCT01018056Medication studyAges 8–17United StatesOCD
Understand this study
Who was this study for?
Listed age limits: 8 years to 17 years.
- Listed locations
- BaltimoreSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNovember 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 39
- Sponsor
- Johns Hopkins University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 8 Years to 17 Years
- Official registry ID
- NCT01018056
- Official title
Show the full official title
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Baltimore
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Johns Hopkins University, a university.
Did this study involve medication?
Yes. The study involved medication, including D-serine, Riluzole and Placebo.
Who was this study for?
Listed age limits: 8 years to 17 years.
